142 related articles for article (PubMed ID: 22043625)
1. [Update on the pathophysiology of Parkinson' disease].
Duyckaerts C; Sazdovitch V; Seilhean D
Bull Acad Natl Med; 2010 Oct; 194(7):1287-303; discussion 1303-4. PubMed ID: 22043625
[TBL] [Abstract][Full Text] [Related]
2. [The mechanism of Lewy body formation in Parkinson's disease].
Wakabayashi K; Takahashi H
Nihon Rinsho; 2000 Oct; 58(10):2022-7. PubMed ID: 11068441
[TBL] [Abstract][Full Text] [Related]
3. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
[TBL] [Abstract][Full Text] [Related]
4. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
6. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death.
Greffard S; Verny M; Bonnet AM; Seilhean D; Hauw JJ; Duyckaerts C
Neurobiol Aging; 2010 Jan; 31(1):99-103. PubMed ID: 18457903
[TBL] [Abstract][Full Text] [Related]
7. A Drosophila model of Parkinson's disease.
Feany MB; Bender WW
Nature; 2000 Mar; 404(6776):394-8. PubMed ID: 10746727
[TBL] [Abstract][Full Text] [Related]
8. Synphilin-1 is present in Lewy bodies in Parkinson's disease.
Wakabayashi K; Engelender S; Yoshimoto M; Tsuji S; Ross CA; Takahashi H
Ann Neurol; 2000 Apr; 47(4):521-3. PubMed ID: 10762166
[TBL] [Abstract][Full Text] [Related]
9. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
10. Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the alpha-synuclein gene.
Yamaguchi K; Cochran EJ; Murrell JR; Polymeropoulos MH; Shannon KM; Crowther RA; Goedert M; Ghetti B
Acta Neuropathol; 2005 Sep; 110(3):298-305. PubMed ID: 15981014
[TBL] [Abstract][Full Text] [Related]
11. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
Jellinger KA
Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
[TBL] [Abstract][Full Text] [Related]
12. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia.
Zarranz JJ; Alegre J; Gómez-Esteban JC; Lezcano E; Ros R; Ampuero I; Vidal L; Hoenicka J; Rodriguez O; Atarés B; Llorens V; Gomez Tortosa E; del Ser T; Muñoz DG; de Yebenes JG
Ann Neurol; 2004 Feb; 55(2):164-73. PubMed ID: 14755719
[TBL] [Abstract][Full Text] [Related]
13. [Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and alpha-synuclein].
Iwatsubo T
Rinsho Shinkeigaku; 1999 Dec; 39(12):1285-6. PubMed ID: 10791099
[TBL] [Abstract][Full Text] [Related]
14. Novel alpha-synuclein-immunoreactive proteins in brain samples from the Contursi kindred, Parkinson's, and Alzheimer's disease.
Langston JW; Sastry S; Chan P; Forno LS; Bolin LM; Di Monte DA
Exp Neurol; 1998 Dec; 154(2):684-90. PubMed ID: 9878203
[TBL] [Abstract][Full Text] [Related]
15. alpha-Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice.
Shirakashi Y; Kawamoto Y; Tomimoto H; Takahashi R; Ihara M
Acta Neuropathol; 2006 Dec; 112(6):681-9. PubMed ID: 16957925
[TBL] [Abstract][Full Text] [Related]
16. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
17. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.
Irizarry MC; Growdon W; Gomez-Isla T; Newell K; George JM; Clayton DF; Hyman BT
J Neuropathol Exp Neurol; 1998 Apr; 57(4):334-7. PubMed ID: 9600226
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
19. [Lewy bodies, a misleading marker for Parkinson's disease?].
Duyckaerts C; Hauw JJ
Bull Acad Natl Med; 2003; 187(2):277-92; discussion 292-3. PubMed ID: 14556441
[TBL] [Abstract][Full Text] [Related]
20. Proteomic approach to studying Parkinson's disease.
Zhang J; Goodlett DR
Mol Neurobiol; 2004 Jun; 29(3):271-88. PubMed ID: 15181239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
